

S134 FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL

Topic: Novel combinations in the treatment of AML

Nigel Russell^{*1}, Jad Othman², Richard Dillon², Nicola Potter², Charlotte Wilhelm-Benartzi³, Steven Knapper⁴, Leona Batten³, Joanna Canham³, Emily Laura Hinson³, Ulrik Malthe Overgaard⁵, Amanda Gilkes⁴, Priyanka Mehta⁶, Panagiotis Kottaridis⁷, Jamie Cavenagh⁸, Claire Hemmaway⁹, Claire Arnold¹⁰, Sylvie Freeman¹¹, Mike Dennis¹²

¹Guy's And St Thomas' Nhs Foundation Trust, London, United Kingdom; ²Department Of Medical And Molecular Genetics, Kings College London, London, United Kingdom; ³Centre For Trials Research, Cardiff University, Cardiff, United Kingdom; ⁴School Of Medicine, Cardiff University, Cardiff, United Kingdom; ⁵Copenhagen University Hospital, Copenhagen, Denmark; ⁶University Hospitals Of Bristol And Weston Nhs Trust, Bristol, United Kingdom; ⁷University College London Hospitals Nhs Foundation Trust, London, United Kingdom; ⁸Department Of Haematology, St Bartholomew's Hospital, London, United Kingdom; ⁹Auckland Hospital, Auckland, Australia; ¹⁰Belfast City Hospital, Belfast, United Kingdom; ¹¹Institute Of Immunology And Immunotherapy, University Of Birmingham, Birmingham, United Kingdom; ¹²On Behalf Of The Uk Ncri Aml Working Group, The Christie Nhs Foundation Trust, Manchester, United Kingdom

Background:

The NCRI AML17 trial established the prognostic impact of measurable residual disease (MRD) by RT-qPCR in patients with *NPM1*^{mut} AML. Patients testing MRD+ve in the peripheral blood (PB) following the second course of chemotherapy (PC2) had a high risk of relapse (77% at 3 years) and poor overall survival (OS, 25% at 3 years). The subsequent NCRI AML19 trial randomised 1033 patients with newly diagnosed AML or MDS-EB2 between FLAG-Ida and DA3+10 and either a single dose of GO (GO1) or a fractionated schedule (GO2). No *FLT3* inhibition was used. The outcomes for this trial have been reported with no OS benefit (Russell et al, ASH, 2022), however in *NPM1*^{mut} patients (n=307) there was an OS benefit with FLAG-Ida-GO (5y OS 82% vs 64%, HR 0.50, CI 0.31-0.81, p <0.005).

Aims:

To analyse the impact of FLAG-Ida-GO on MRD and outcome of post-induction therapy in *NPM1*^{mut} AML with and without a *FLT3* mutation

Methods:

NPM1^{mut} MRD was measured following each chemotherapy course. Patients who were PC2 PB MRD+ve were recommended for transplant in CR1 Post-remission therapy for MRD-ve patients consisted of up to 2 courses of HDAC.

Results:

The survival benefit for FLAG-Ida-GO was seen in both *FLT3*^{mut} (HR 0.32, 95CI 0.17-0.62) and *FLT3*^{wt} patients (HR 0.75, 95CI 0.37-1.51) with no evidence of differential benefit on tests for heterogeneity (Figure 1). FLAG-Ida-GO increased the number of patients who were PC2 PB MRD-ve (88% vs 77% with DA-GO, p=0.02), as well as the number with an MRD-ve bone marrow (BM) both PC2 (56% vs 37%, p=0.004) and at end of treatment (70% vs 58%, p=0.32). In those with undetectable PB MRD, the BM response was deeper in the FLAG-Ida-GO arm, with 60% also BM MRD-ve compared to 47% with DA-GO (p=0.069). The same trend for a deeper BM response was

Copyright Information: (Online) ISSN: 2572-9241

© 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2023;7(S3):pages. The individual abstract DOIs can be found at <https://journals.lww.com/hemasphere/pages/default.aspx>.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.

seen in those who were PB PC2 MRD+ve. The improved FLAG-Ida-GO MRD response was seen in both *FLT3*^{mut} (PC2 PB-ve 83% vs 68%) and *FLT3*^{wt} (PC2 PB-ve 92% vs 82%). Within the DAGO arm, GO2 resulted in an increase in the number testing PB PC2 MRD-ve (84% vs 69% for GO1, p=0.04) but did not improve survival. There was no effect of GO dose on MRD in the FLAG-Ida-GO arm.

For PB PC2 MRD+ve patients, 61% proceeded to transplant in CR and this did not differ by randomisation. For these patients 3y OS was 59%, those randomised to FLAG-Ida-GO had a trend to better survival than those allocated DA-GO (74% vs 51% at 3 years, HR 0.52, 95CI 0.17-1.57). For PC2 PB MRD-ve patients, outcomes were excellent with both therapies, but here again survival was superior in patients treated with FLAG-Ida-GO (3y OS 90% vs 78%, HR 0.43, 95CI 0.22-0.87). There was no heterogeneity in the FLAG-Ida-GO benefit based on MRD response (Figure 1). Patients could receive up to 2 cycles of consolidation with HDAC, for patients who were PB MRD-ve after FLAG-Ida-GO (n=115) there was no evidence that overall or relapse-free survival (RFS) was improved by consolidation (for 0, 1 and 2 cycles of consolidation respectively, 3 year OS 90% vs 83% vs 93%, p=0.53; 3 year RFS 75% vs 65% vs 81%, p=0.14)

Summary/Conclusion:

FLAG-Ida-GO improved the OS of patients with *NPM1*^{mut} AML and reduced the number who were PB PC2 MRD+ve compared to DA-GO. This survival benefit was independent of *FLT3* mutation status and was seen in both PB PC2 MRD+ve and MRD-ve patients and was supported by the finding that BM MRD levels in both groups were lower with FLAG-Ida-GO including those testing PB post C2 negative. For those patients who were PB MRD-ve after 2 cycles of FLAG-Ida-GO, this treatment appears sufficient.

Copyright Information: (Online) ISSN: 2572-9241

© 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2023;7(S3):pages. The individual abstract DOIs can be found at <https://journals.lww.com/hemasphere/pages/default.aspx>.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.




Figure 1 – overall survival by randomisation arm.

A. By NPM1 and FLT3 status

B. By Post course 2 peripheral blood MRD result

Copyright Information: (Online) ISSN: 2572-9241

© 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2023;7(S3):pages. The individual abstract DOIs can be found at <https://journals.lww.com/hemasphere/pages/default.aspx>.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.